Brynne L, Karlsson M O, Paalzow L K
Department of Pharmacy, Division of Biopharmaceutics and Pharmacokinetics, Uppsala University, Uppsala, Sweden.
J Pharmacol Exp Ther. 1998 Sep;286(3):1152-8.
The concentration-effect relationship of l-propranolol and dl-metoprolol were investigated in spontaneous hypertensive rats using reduction in exercise-induced tachycardia as a pharmacodynamic endpoint. The influence of protein binding on the effect relationship was also assessed. The rats were assigned to treatment or placebo groups, where each group received three randomly selected consecutively increasing steady-state infusions. Different pharmacodynamic effect models were fitted to the data, using nonlinear mixed effect modeling. The data were best described by a combined effect model, with a sum of an ordinary Imax and a linear model. At the lower concentration range, the ordinary Imax model dominated, although at higher concentrations, the effect was linearly related to the antagonist concentration. The Imax were 83 +/- 6 and 103 +/- 6 beats . min-1 and the IC50 were 18.1 +/- 4.3 and 50.6 +/- 15.2 ng/ml for l-propranolol and dl-metoprolol, respectively. The slope in the linear model was steeper for l-propranolol than for dl-metoprolol, 28.9 +/- 2.8 and 4.48 +/- 0.39 beats . ml . (min . microgram)-1, respectively. Plasma protein binding of l-propranolol was saturable. The unbound IC50 for l-propranolol was 1.14 +/- 0.27 ng/ml. The concentration-effect relationship of l-propranolol was altered at higher plasma concentrations, due to saturable protein binding. The Imax and the linear concentration-effect relationship may be interpreted as a specific beta-antagonist effect and a membrane-stabilizing effect, respectively. Using exercise-induced tachycardia as a pharmacodynamic endpoint, to study the effect of beta-antagonists in spontaneous hypertensive rats, seems to give reliable results and can be a useful model to extrapolate to humans.
以运动诱发的心动过速的降低作为药效学终点,研究了左旋普萘洛尔和消旋美托洛尔在自发性高血压大鼠中的浓度-效应关系。还评估了蛋白结合对效应关系的影响。将大鼠分为治疗组或安慰剂组,每组接受三次随机选择的连续递增的稳态输注。使用非线性混合效应模型将不同的药效学效应模型拟合到数据中。数据最好用一个组合效应模型来描述,该模型由一个普通的Imax和一个线性模型相加而成。在较低浓度范围内,普通的Imax模型占主导,尽管在较高浓度下,效应与拮抗剂浓度呈线性相关。左旋普萘洛尔和消旋美托洛尔的Imax分别为83±6和103±6次·分钟-1,IC50分别为18.1±4.3和50.6±15.2 ng/ml。左旋普萘洛尔线性模型中的斜率比消旋美托洛尔更陡,分别为28.9±2.8和4.48±0.39次·毫升·(分钟·微克)-1。左旋普萘洛尔的血浆蛋白结合是可饱和的。左旋普萘洛尔的游离IC50为1.14±0.27 ng/ml。由于可饱和的蛋白结合,左旋普萘洛尔的浓度-效应关系在较高血浆浓度下发生改变。Imax和线性浓度-效应关系可分别解释为特异性β受体拮抗效应和膜稳定效应。以运动诱发的心动过速作为药效学终点,研究β受体拮抗剂在自发性高血压大鼠中的作用,似乎能给出可靠的结果,并且可以作为推断人体情况的有用模型。